Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis-Reference-Cited by-同舟云学术

Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis

Published:2024-07-31 Issue: Volume: Page:
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Blauvelt Andrew¹,Conrad Curdin²,Noe Megan H.³

Affiliation:

1. Blauvelt Consulting, LLC, Lake Oswego, Oregon

2. Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland

3. Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2821681/jamadermatology_blauvelt_2024_ed_240008_1722027529.86827.pdf

Reference11 articles.

1. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator’s Global Assessment scores predict complete skin clearance.;Reich;J Eur Acad Dermatol Venereol,2022

2. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.;Schäkel;J Eur Acad Dermatol Venereol,2023

3. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.;Augustin;Br J Dermatol,2022

4. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: a randomized clinical trial.;Eyerich;JAMA Dermatol,2024

5. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).;Blauvelt;Br J Dermatol,2017